US5242794A
(en)
*
|
1984-12-13 |
1993-09-07 |
Applied Biosystems, Inc. |
Detection of specific sequences in nucleic acids
|
CA2001401A1
(en)
*
|
1988-10-25 |
1990-04-25 |
Claude Piantadosi |
Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
|
US6358931B1
(en)
|
1990-01-11 |
2002-03-19 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating RNA
|
US6783931B1
(en)
|
1990-01-11 |
2004-08-31 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
US6005087A
(en)
*
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US20040142899A1
(en)
*
|
1990-01-11 |
2004-07-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US6339066B1
(en)
|
1990-01-11 |
2002-01-15 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
|
US5635488A
(en)
*
|
1991-10-15 |
1997-06-03 |
Isis Pharmaceuticals, Inc. |
Compounds having phosphorodithioate linkages of high chiral purity
|
US5872232A
(en)
*
|
1990-01-11 |
1999-02-16 |
Isis Pharmaceuticals Inc. |
2'-O-modified oligonucleotides
|
US5620963A
(en)
*
|
1991-10-15 |
1997-04-15 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US5587361A
(en)
*
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
US7037646B1
(en)
|
1990-01-11 |
2006-05-02 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US5959096A
(en)
*
|
1992-03-16 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US5859221A
(en)
*
|
1990-01-11 |
1999-01-12 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US5834607A
(en)
*
|
1990-07-27 |
1998-11-10 |
Isis Pharmaceuticals, Inc. |
Amines and methods of making and using the same
|
US5386023A
(en)
*
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
US5541307A
(en)
*
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
US5783682A
(en)
*
|
1990-07-27 |
1998-07-21 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide mimics having nitrogen-containing linkages
|
US5602240A
(en)
*
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
DK0541722T3
(da)
*
|
1990-08-03 |
1996-04-22 |
Sterling Winthrop Inc |
Forbindelser og fremgangsmåder til inhibering af genekspression
|
US6153595A
(en)
*
|
1990-08-16 |
2000-11-28 |
Isis Pharmaceuticals Inc. |
Composition and method for treatment of CMV infections
|
JPH06505704A
(ja)
*
|
1990-09-20 |
1994-06-30 |
ギリアド サイエンシズ,インコーポレイテッド |
改変ヌクレオシド間結合
|
US5965722A
(en)
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
FR2679255B1
(fr)
*
|
1991-07-17 |
1993-10-22 |
Bio Merieux |
Procede d'immobilisation d'un fragment nucleique par fixation passive sur un support solide, support solide ainsi obtenu et son utilisation.
|
US5599797A
(en)
*
|
1991-10-15 |
1997-02-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
US5661134A
(en)
*
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
US5607923A
(en)
*
|
1991-10-15 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
|
US5576302A
(en)
*
|
1991-10-15 |
1996-11-19 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
|
US5654284A
(en)
*
|
1991-10-15 |
1997-08-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
US5359044A
(en)
*
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
EP0635023B1
(de)
*
|
1992-03-05 |
2002-02-06 |
Isis Pharmaceuticals, Inc. |
Kovalent vernetzte oligonukleotide
|
US5922686A
(en)
*
|
1992-03-16 |
1999-07-13 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of protein kinase C
|
WO1993019203A1
(en)
*
|
1992-03-16 |
1993-09-30 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of protein kinase c
|
US6153599A
(en)
*
|
1992-03-16 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
|
US5882927A
(en)
*
|
1992-03-16 |
1999-03-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of protein kinase C
|
US5948898A
(en)
*
|
1992-03-16 |
1999-09-07 |
Isis Pharmaceuticals, Inc. |
Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
|
US5885970A
(en)
*
|
1992-03-16 |
1999-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US5916807A
(en)
*
|
1992-03-16 |
1999-06-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
US6117847A
(en)
*
|
1992-03-16 |
2000-09-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for enhanced modulation of protein kinase C expression
|
US6537973B1
(en)
|
1992-03-16 |
2003-03-25 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of protein kinase C
|
US5817781A
(en)
|
1992-06-01 |
1998-10-06 |
Gilead Sciences, Inc. |
Modified internucleoside linkages (II)
|
US6174868B1
(en)
|
1992-09-10 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
AU4848793A
(en)
*
|
1992-09-11 |
1994-04-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
|
US6235886B1
(en)
|
1993-09-03 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Methods of synthesis and use
|
CA2105595A1
(en)
*
|
1992-09-23 |
1994-03-24 |
Ramaswamy Narayanan |
Antisense polynucleotides
|
WO1994007367A1
(en)
*
|
1992-09-29 |
1994-04-14 |
Apollon, Inc. |
Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
|
US5985558A
(en)
|
1997-04-14 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
|
US20030013670A1
(en)
*
|
1992-10-05 |
2003-01-16 |
Monia Brett P. |
Antisense oligonucleotide inhibition of ras
|
US5872242A
(en)
*
|
1992-10-05 |
1999-02-16 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of ras
|
AU680449B2
(en)
*
|
1992-10-05 |
1997-07-31 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of the ras gene
|
US6784290B1
(en)
|
1992-10-05 |
2004-08-31 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of ras
|
US5512671A
(en)
*
|
1993-02-16 |
1996-04-30 |
Wake Forest University |
Ether lipid-nucleoside covalent conjugates
|
AU7019794A
(en)
*
|
1993-05-26 |
1994-12-20 |
Genta Incorporated |
Oligomer conjugates and their use
|
ATE226437T1
(de)
*
|
1993-06-10 |
2002-11-15 |
Univ Wake Forest |
(phospho)lipide zum bekämpfen einer hepatitis b- infektion
|
US5428149A
(en)
*
|
1993-06-14 |
1995-06-27 |
Washington State University Research Foundation |
Method for palladium catalyzed carbon-carbon coulping and products
|
HUT74597A
(en)
*
|
1993-06-23 |
1997-01-28 |
Genesys Pharma Inc |
Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
|
US6294664B1
(en)
|
1993-07-29 |
2001-09-25 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides
|
AU679566B2
(en)
|
1993-09-03 |
1997-07-03 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US6653458B1
(en)
|
1993-09-03 |
2003-11-25 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides
|
DE4331670A1
(de)
*
|
1993-09-17 |
1995-03-23 |
Hoechst Ag |
Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
|
US5801154A
(en)
*
|
1993-10-18 |
1998-09-01 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of multidrug resistance-associated protein
|
AU6168294A
(en)
*
|
1994-01-31 |
1995-08-15 |
University Of Medicine And Dentistry Of New Jersey |
Triplex-forming paired-ion oligonucleotides and methods for preparing and using same
|
DE4408528A1
(de)
*
|
1994-03-14 |
1995-09-28 |
Hoechst Ag |
Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
|
US6919441B2
(en)
|
1994-03-14 |
2005-07-19 |
Aventis Pharma Deutschland Gmbh |
Polyamide-oligonucleotide derivatives, their preparation and use
|
US6391636B1
(en)
|
1994-05-31 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US5981731A
(en)
*
|
1994-05-31 |
1999-11-09 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of B-raf gene expression
|
US7135584B2
(en)
|
1995-08-07 |
2006-11-14 |
Wake Forest University |
Lipid analogs for treating viral infections
|
EP1852121A3
(de)
|
1994-08-29 |
2007-11-21 |
Wake Forest University |
Flüssige Analoge zur Behandlung viraler Infektionen
|
EP0888128A2
(de)
|
1995-02-10 |
1999-01-07 |
The Worcester Foundation For Biomedical Research |
Abgabe von exogenen verbindungen
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US5959100A
(en)
|
1996-03-27 |
1999-09-28 |
Nexstar Pharmaceuticals, Inc. |
Pyrimidine nucleosides as therapeutic and diagnostic agents
|
US5856099A
(en)
*
|
1996-05-21 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Antisense compositions and methods for modulating type I interleukin-1 receptor expression
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US6111085A
(en)
*
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
US6001991A
(en)
*
|
1996-10-04 |
1999-12-14 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
|
US6319906B1
(en)
|
1996-12-31 |
2001-11-20 |
Isis Pharmaceuticals |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US7235653B2
(en)
*
|
1996-12-31 |
2007-06-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6077833A
(en)
*
|
1996-12-31 |
2000-06-20 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US20040023917A1
(en)
*
|
1996-12-31 |
2004-02-05 |
Bennett C. Frank |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6576752B1
(en)
|
1997-02-14 |
2003-06-10 |
Isis Pharmaceuticals, Inc. |
Aminooxy functionalized oligomers
|
US6127533A
(en)
*
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
JP2002510319A
(ja)
|
1997-07-01 |
2002-04-02 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
|
US5877309A
(en)
*
|
1997-08-13 |
1999-03-02 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against JNK
|
US6133246A
(en)
*
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US20070149472A1
(en)
*
|
1997-08-13 |
2007-06-28 |
Mckay Robert |
Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
|
US6809193B2
(en)
|
1997-08-13 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US5948902A
(en)
|
1997-11-20 |
1999-09-07 |
South Alabama Medical Science Foundation |
Antisense oligonucleotides to human serine/threonine protein phosphatase genes
|
US20040171564A1
(en)
*
|
1997-11-20 |
2004-09-02 |
Honkanen Richard E. |
Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression
|
US6673914B1
(en)
|
1998-01-22 |
2004-01-06 |
John Wayne Cancer Institute |
Human tumor-associated gene
|
US5968748A
(en)
*
|
1998-03-26 |
1999-10-19 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human HER-2 expression
|
US7321828B2
(en)
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
WO1999060012A1
(en)
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
WO1999060167A1
(en)
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
US6300319B1
(en)
|
1998-06-16 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Targeted oligonucleotide conjugates
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6673912B1
(en)
|
1998-08-07 |
2004-01-06 |
Isis Pharmaceuticals, Inc. |
2′-O-aminoethyloxyethyl-modified oligonucleotides
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
US20040009938A1
(en)
*
|
1998-08-07 |
2004-01-15 |
Muthiah Manoharan |
Methods of enhancing renal uptake of oligonucleotides
|
US6175004B1
(en)
|
1998-09-01 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6069243A
(en)
*
|
1998-10-06 |
2000-05-30 |
Isis Pharmaceuticals, Inc. |
Process for oligonucleotide synthesis
|
US6492111B1
(en)
|
1998-11-25 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
In situ binary synthesis of biologically effective molecules
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
US6403779B1
(en)
|
1999-01-08 |
2002-06-11 |
Isis Pharmaceuticals, Inc. |
Regioselective synthesis of 2′-O-modified nucleosides
|
US6127124A
(en)
*
|
1999-01-20 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
Fluorescence based nuclease assay
|
US6399765B1
(en)
*
|
1999-03-17 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Methods for removing dimethoxytrityl groups from oligonucleotides
|
US6235891B1
(en)
|
1999-03-31 |
2001-05-22 |
South Alabama Medical Science Foundation |
Glucocorticoid receptor agonist and decreased PP5
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US8541548B2
(en)
*
|
1999-06-07 |
2013-09-24 |
Arrowhead Madison Inc. |
Compounds and methods for reversible modification of biologically active molecules
|
US20080281041A1
(en)
*
|
1999-06-07 |
2008-11-13 |
Rozema David B |
Reversibly Masked Polymers
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6147200A
(en)
*
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US6277982B1
(en)
|
1999-08-20 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates
|
US7026469B2
(en)
*
|
2000-10-19 |
2006-04-11 |
Wake Forest University School Of Medicine |
Compositions and methods of double-targeting virus infections and cancer cells
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
EP1265995A2
(de)
*
|
2000-02-11 |
2002-12-18 |
Ribozyme Pharmaceuticals, Inc. |
Verfahren und reagenzien zur modulation und diagnose der expression von den cd20 und nogo genen
|
US20080039414A1
(en)
*
|
2002-02-20 |
2008-02-14 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20050233329A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
Inhibition of gene expression using duplex forming oligonucleotides
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
US8273866B2
(en)
*
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US8202979B2
(en)
*
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US7105962B2
(en)
*
|
2000-08-03 |
2006-09-12 |
Matsushita Electric Industrial Co., Ltd. |
Brushless motor for partable electronic equipment with wire treatment technique of coils
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US20050209179A1
(en)
*
|
2000-08-30 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US20080032942A1
(en)
*
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
WO2002030465A2
(en)
|
2000-10-12 |
2002-04-18 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
US7309696B2
(en)
|
2000-10-19 |
2007-12-18 |
Wake Forest University |
Compositions and methods for targeting cancer cells
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
KR20020069627A
(ko)
*
|
2001-02-27 |
2002-09-05 |
동부한농화학 주식회사 |
육환의 아자슈거를 가진 뉴클레오타이드 유도체를 포함한포스포로티오에이트 올리고뉴클레오타이드 및 이들의에이즈 치료제로서의 새로운 용도
|
WO2002092616A1
(en)
|
2001-05-11 |
2002-11-21 |
Orasense, Ltd. |
Antisense permeation enhancers
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
US20050164966A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050079610A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US20050256068A1
(en)
*
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20050164967A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20050124567A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20050130181A1
(en)
*
|
2001-05-18 |
2005-06-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
|
US20060142226A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
|
US20040219671A1
(en)
*
|
2002-02-20 |
2004-11-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
|
US7517864B2
(en)
*
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20060019913A1
(en)
*
|
2001-05-18 |
2006-01-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050176664A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
|
US20050182006A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050159380A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
|
US20060142225A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
|
US20050136436A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20080188430A1
(en)
*
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050137155A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20050176665A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050119211A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
|
US20050148530A1
(en)
*
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050054596A1
(en)
*
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20050124568A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20050054598A1
(en)
*
|
2002-02-20 |
2005-03-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050227935A1
(en)
*
|
2001-05-18 |
2005-10-13 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
|
US20050080031A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050164224A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20050182009A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
|
US20050209180A1
(en)
*
|
2001-05-18 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20040209831A1
(en)
*
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
US20050153915A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
|
US20050159376A1
(en)
*
|
2002-02-20 |
2005-07-21 |
Slrna Therapeutics, Inc. |
RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
*
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US20050233996A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050159379A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
US20060241075A1
(en)
*
|
2001-05-18 |
2006-10-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
|
US20050191638A1
(en)
*
|
2002-02-20 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
WO2002096826A2
(en)
*
|
2001-05-29 |
2002-12-05 |
Koninklijke Philips Electronics N.V. |
Metal-ceramic bond
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
DK2000545T3
(da)
|
2001-06-20 |
2011-11-28 |
Genentech Inc |
Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
|
AU2002315393A1
(en)
|
2001-06-21 |
2003-01-08 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
JP4714413B2
(ja)
*
|
2001-08-31 |
2011-06-29 |
トムソン ライセンシング |
オーディオビジュアルストリームのためのシーケンスカウンタ
|
NZ573740A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly kidney tumor - TAT184
|
ATE516364T1
(de)
|
2001-10-09 |
2011-07-15 |
Isis Pharmaceuticals Inc |
Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US20050075304A1
(en)
*
|
2001-11-30 |
2005-04-07 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20070203333A1
(en)
*
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20040138163A1
(en)
*
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
AU2002367318B2
(en)
|
2002-01-02 |
2007-07-12 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20050096284A1
(en)
*
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20050137153A1
(en)
*
|
2002-02-20 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
|
US20050222064A1
(en)
*
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20030191075A1
(en)
*
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
US8138383B2
(en)
*
|
2002-03-11 |
2012-03-20 |
Arrowhead Madison Inc. |
Membrane active heteropolymers
|
US8008355B2
(en)
*
|
2002-03-11 |
2011-08-30 |
Roche Madison Inc. |
Endosomolytic poly(vinyl ether) polymers
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
US7169916B2
(en)
*
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
AU2003230874A1
(en)
|
2002-04-16 |
2003-11-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
ATE474045T1
(de)
|
2002-05-30 |
2010-07-15 |
Sloan Kettering Inst Cancer |
Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese
|
US20040092470A1
(en)
*
|
2002-06-18 |
2004-05-13 |
Leonard Sherry A. |
Dry powder oligonucleotide formualtion, preparation and its uses
|
US20040019000A1
(en)
*
|
2002-07-19 |
2004-01-29 |
Muthiah Manoharan |
Polyalkyleneamine-containing oligomers
|
US20040106785A1
(en)
*
|
2002-07-25 |
2004-06-03 |
Micrologix Biotech Inc. |
Inhibitors of RNA dependent RNA polymerase and uses thereof
|
WO2004013160A2
(en)
|
2002-08-05 |
2004-02-12 |
University Of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
US6878805B2
(en)
*
|
2002-08-16 |
2005-04-12 |
Isis Pharmaceuticals, Inc. |
Peptide-conjugated oligomeric compounds
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
KR101360955B1
(ko)
|
2002-09-13 |
2014-02-10 |
레플리코르 인코포레이티드 |
비서열 상보적 항바이러스 올리고뉴클레오티드
|
US20040137471A1
(en)
*
|
2002-09-18 |
2004-07-15 |
Timothy Vickers |
Efficient reduction of target RNA's by single-and double-stranded oligomeric compounds
|
US7229976B2
(en)
|
2002-09-26 |
2007-06-12 |
Isis Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
EP1560839A4
(de)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
Chimäre oligomere verbindungen und derenverwendung in der genmodulation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
EP1560840B1
(de)
|
2002-11-05 |
2015-05-06 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen, die alternierende 2'-modifizierte nucleoside enthalten, zur verwendung in der genmodulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
CA2504694C
(en)
|
2002-11-05 |
2013-10-01 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
JP4986109B2
(ja)
|
2002-11-13 |
2012-07-25 |
ジェンザイム・コーポレーション |
アポリポタンパク質b発現のアンチセンス調節
|
DK2336318T3
(da)
|
2002-11-13 |
2013-07-15 |
Genzyme Corp |
Antisense-modulering af apolipoprotein b-ekspression
|
CA2506127C
(en)
|
2002-11-15 |
2013-07-09 |
Morphotek, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
AU2003298650B2
(en)
|
2002-11-15 |
2010-03-11 |
Musc Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
CA2507044A1
(en)
|
2002-11-21 |
2004-06-10 |
Mary Lucero |
Purinergic modulation of smell
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US20040231231A1
(en)
*
|
2002-12-20 |
2004-11-25 |
Cataldo Dominic A. |
Use of colloidal clays for sustained release of active ingredients
|
CA2515484C
(en)
|
2003-02-11 |
2011-09-20 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US20040198640A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
JP2006522158A
(ja)
*
|
2003-04-03 |
2006-09-28 |
アルナイラム ファーマシューティカルズ インコーポレイテッド |
iRNA複合体
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US7960355B2
(en)
*
|
2003-05-23 |
2011-06-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of the expression of B7 protein
|
US7897582B2
(en)
*
|
2003-05-23 |
2011-03-01 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
CA2540692C
(en)
|
2003-06-02 |
2013-05-28 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
CN1984921B
(zh)
|
2003-06-03 |
2010-06-16 |
Isis药物公司 |
存活蛋白表达的调节
|
DK3604537T3
(da)
|
2003-06-13 |
2022-02-28 |
Alnylam Europe Ag |
Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
|
US7790691B2
(en)
*
|
2003-06-20 |
2010-09-07 |
Isis Pharmaceuticals, Inc. |
Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation
|
WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
NZ545134A
(en)
|
2003-09-18 |
2009-06-26 |
Lilly Co Eli |
Modulation of eIF4E expression
|
CA2538252C
(en)
|
2003-09-18 |
2014-02-25 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
US7125945B2
(en)
*
|
2003-09-19 |
2006-10-24 |
Varian, Inc. |
Functionalized polymer for oligonucleotide purification
|
NZ546272A
(en)
|
2003-10-10 |
2009-05-31 |
Alchemia Oncology Pty Ltd |
The modulation of hyaluronan synthesis and degradation in the treatment of disease
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
ES2472690T3
(es)
|
2003-11-17 |
2014-07-02 |
Genentech, Inc. |
Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
|
EP2363480A3
(de)
|
2004-01-20 |
2015-10-07 |
Isis Pharmaceuticals, Inc. |
Modulierung der Glukokortikoid-Rezeptor-Expression
|
US8778900B2
(en)
*
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US20050187191A1
(en)
*
|
2004-02-20 |
2005-08-25 |
Kucera Louis S. |
Methods and compositions for the treatment of respiratory syncytial virus
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP1730309B1
(de)
|
2004-03-15 |
2016-05-04 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur optimierung der spaltung von rna durch rnase h
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
US20050267300A1
(en)
|
2004-04-05 |
2005-12-01 |
Muthiah Manoharan |
Processes and reagents for oligonucleotide synthesis and purification
|
US7674778B2
(en)
|
2004-04-30 |
2010-03-09 |
Alnylam Pharmaceuticals |
Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
|
DK1773872T3
(en)
|
2004-05-21 |
2017-05-08 |
Uab Res Found |
VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP4047096A1
(de)
|
2004-06-28 |
2022-08-24 |
The University Of Western Australia |
Antisense-oligonukleotide zur induzierung von exon-skipping und verfahren zur verwendung davon
|
WO2006023880A2
(en)
*
|
2004-08-23 |
2006-03-02 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
CA2989941A1
(en)
*
|
2004-09-23 |
2006-03-30 |
Arc Pharmaceuticals, Inc. |
Pharmaceutical compostions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US7923206B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US9944713B2
(en)
|
2004-11-24 |
2018-04-17 |
Medicinal Bioconvergence Research Center |
Antibody specific to the AIMP2-DX2
|
WO2006068398A1
(en)
|
2004-12-20 |
2006-06-29 |
Isu Abxis Co., Ltd. |
Molecules inhibition intercellular adhesion
|
CA2595407A1
(en)
|
2005-01-20 |
2006-07-27 |
University Of Rochester |
Thioredoxin interacting protein (txnip) as regulator of vascular function
|
CN101193905B
(zh)
|
2005-02-11 |
2014-06-25 |
纪念斯隆-凯特林癌症中心 |
用于检测抗药egfr突变体的方法和组合物
|
KR20070110077A
(ko)
|
2005-03-10 |
2007-11-15 |
제넨테크, 인크. |
혈관 완전성을 조정하기 위한 방법 및 조성물
|
US7476733B2
(en)
|
2005-03-25 |
2009-01-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
|
WO2007008300A2
(en)
|
2005-05-31 |
2007-01-18 |
ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
US8252756B2
(en)
|
2005-06-14 |
2012-08-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
US20090176725A1
(en)
*
|
2005-08-17 |
2009-07-09 |
Sirna Therapeutics Inc. |
Chemically modified short interfering nucleic acid molecules that mediate rna interference
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
CA2625891A1
(en)
|
2005-10-14 |
2007-04-26 |
Carlton D. Donald |
Inhibition of pax2 by defb1 induction as a therapy for cancer
|
JP5111385B2
(ja)
*
|
2005-10-28 |
2013-01-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ハンチンチン遺伝子の発現を抑制するための組成物および方法
|
AU2006311730B2
(en)
|
2005-11-09 |
2010-12-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Factor V Leiden mutant gene
|
EP1966377A2
(de)
|
2005-11-21 |
2008-09-10 |
Isis Pharmaceuticals, Inc. |
Modulation der eif4e-bp2-expression
|
EP1976567B1
(de)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natürliche antisense- und nicht-kodierende rna-transkripte als arzneitargets
|
WO2007115168A2
(en)
|
2006-03-31 |
2007-10-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
WO2008005479A2
(en)
*
|
2006-07-06 |
2008-01-10 |
University Of Wyoming |
Charge reversible polymers
|
CN101437943A
(zh)
|
2006-05-03 |
2009-05-20 |
波罗的科技发展有限公司 |
牢固结合的碱基-修饰的寡核苷酸和人工核酸酶组合的反义药剂
|
EP3249052B1
(de)
|
2006-05-11 |
2019-04-10 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der pcsk9-genexpression
|
JP2009537153A
(ja)
|
2006-05-19 |
2009-10-29 |
アルニラム ファーマシューティカルズ, インコーポレイテッド |
AhaのRNAi調節およびその治療上の使用
|
EP2018443A4
(de)
|
2006-05-22 |
2009-11-11 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur hemmung der ikk-b-genexpression
|
WO2008097328A2
(en)
*
|
2006-06-23 |
2008-08-14 |
Northwestern University |
Asymmetric functionalized nanoparticles and methods of use
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
CA2660052A1
(en)
*
|
2006-08-04 |
2008-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of jnk proteins
|
WO2008022309A2
(en)
*
|
2006-08-18 |
2008-02-21 |
F. Hoffmann-La Roche Ag |
Polyconjugates for in vivo delivery of polynucleotides
|
AU2007299629C1
(en)
|
2006-09-21 |
2012-05-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the HAMP gene
|
CA2663601C
(en)
|
2006-09-22 |
2014-11-25 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by rna interference
|
CA3144493A1
(en)
|
2006-10-03 |
2008-04-10 |
Arbutus Biopharma Corporation |
Lipid containing formulations
|
EP2104516B1
(de)
|
2006-11-01 |
2015-01-07 |
University of Rochester |
Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
|
US7994130B2
(en)
|
2006-12-11 |
2011-08-09 |
University Of Utah Research Foundation |
Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability
|
US7947447B2
(en)
|
2007-01-16 |
2011-05-24 |
Somalogic, Inc. |
Method for generating aptamers with improved off-rates
|
JP5512285B2
(ja)
|
2007-02-09 |
2014-06-04 |
ノースウェスタン ユニバーシティ |
細胞内標的を検出するための粒子
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
EP2589660B1
(de)
|
2007-03-29 |
2014-11-26 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Ebola-Genexpression
|
AU2008242842B2
(en)
*
|
2007-04-17 |
2014-06-05 |
Baxter Healthcare Sa |
Nucleic acid microparticles for pulmonary delivery
|
EP2826863B1
(de)
|
2007-05-30 |
2017-08-23 |
Northwestern University |
Nukleinsäurefunktionalisierte Nanopartikel für therapeutische Anwendungen
|
CN101688206B
(zh)
|
2007-07-05 |
2013-05-15 |
诺瓦提斯公司 |
用于治疗病毒感染的dsRNA
|
US8404830B2
(en)
*
|
2007-07-17 |
2013-03-26 |
Somalogic, Inc. |
Method for generating aptamers with improved off-rates
|
JP2010538005A
(ja)
|
2007-08-28 |
2010-12-09 |
ユーエービー リサーチ ファウンデーション |
合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
WO2009039466A1
(en)
|
2007-09-20 |
2009-03-26 |
Vanderbilt University |
Free solution measurement of molecular interactions by backscattering interferometry
|
WO2009039442A1
(en)
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
JP2010539978A
(ja)
|
2007-10-02 |
2010-12-24 |
アムジェン インコーポレイテッド |
マイクロ−rnaおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加
|
US8916531B2
(en)
|
2007-11-20 |
2014-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US7845686B2
(en)
*
|
2007-12-17 |
2010-12-07 |
S & B Technical Products, Inc. |
Restrained pipe joining system for plastic pipe
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
CA2716793A1
(en)
|
2008-03-05 |
2009-09-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
EP2105145A1
(de)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
|
EP2274423A2
(de)
*
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
|
CA2721183C
(en)
|
2008-04-11 |
2019-07-16 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
US20110262485A1
(en)
|
2008-08-04 |
2011-10-27 |
University Of Miami |
Sting (stimulator of interferon genes), a regulator of innate immune responses
|
DK2331141T3
(en)
|
2008-08-25 |
2016-04-04 |
Excaliard Pharmaceuticals Inc |
Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
|
WO2010028054A1
(en)
|
2008-09-02 |
2010-03-11 |
Alnylam Europe Ag. |
Compositions and methods for inhibiting expression of mutant egfr gene
|
EP3587434A1
(de)
|
2008-09-23 |
2020-01-01 |
Alnylam Pharmaceuticals Inc. |
Chemische modifikationen von monomeren und oligonukleotiden mit click komponenten um liganden zu konjugieren
|
EP3109321B1
(de)
|
2008-09-25 |
2019-05-01 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
|
EP2352830B1
(de)
|
2008-10-03 |
2019-01-16 |
CuRNA, Inc. |
Behandlung von krankheiten in verbindung mit apolipoprotein a1 durch hemmung eines natürlichen antisense-transkripts gegen apolipoprotein a1
|
EA020312B1
(ru)
|
2008-10-20 |
2014-10-30 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы для ингибирования экспрессии транстиретина
|
EP2358398A2
(de)
|
2008-10-24 |
2011-08-24 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen und verfahren
|
EP3428278A1
(de)
|
2008-10-24 |
2019-01-16 |
Sarepta Therapeutics, Inc. |
Mehrere exon-skipping-zusammensetzungen für dmd
|
KR102042721B1
(ko)
|
2008-11-10 |
2019-11-11 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
WO2010060110A1
(en)
|
2008-11-24 |
2010-05-27 |
Northwestern University |
Polyvalent rna-nanoparticle compositions
|
BRPI0923225A2
(pt)
|
2008-12-02 |
2016-10-04 |
Chiralgen Ltd |
metodo para sintese de acidos nucleicos modificados no atomo de fosforo
|
US8927511B2
(en)
|
2008-12-04 |
2015-01-06 |
Curna, Inc. |
Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
|
US20110237649A1
(en)
|
2008-12-04 |
2011-09-29 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
US20110294870A1
(en)
|
2008-12-04 |
2011-12-01 |
Opko Curna, Llc |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
US8921329B2
(en)
|
2008-12-04 |
2014-12-30 |
Curna, Inc. |
Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
|
EP2373382B1
(de)
|
2008-12-10 |
2017-02-15 |
Alnylam Pharmaceuticals, Inc. |
Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
WO2010091308A2
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
DK2396038T3
(en)
|
2009-02-12 |
2016-02-01 |
Curna Inc |
TREATMENT OF BRAIN-DERIVATED NEUROTROPHIC FACTOR- (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
|
KR101805199B1
(ko)
|
2009-02-12 |
2017-12-05 |
큐알엔에이, 인크. |
신경교세포 유래된 신경영양성 인자 (gdnf)에 대한 자연 안티센스 전사체의 저해에 의한 신경교세포 유래된 신경영양성 인자 (gdnf) 관련된 질환의 치료
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
AU2010221419B2
(en)
|
2009-03-02 |
2015-10-01 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
WO2010102058A2
(en)
|
2009-03-04 |
2010-09-10 |
Curna, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
|
CA2754043A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
EP2408919B1
(de)
|
2009-03-16 |
2017-10-18 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
|
EP2408920B1
(de)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
EA201171144A1
(ru)
|
2009-03-19 |
2012-04-30 |
Мерк Шарп Энд Домэ Корп. |
ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
WO2010107958A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2012520685A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害
|
JP2012521764A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害
|
EP2411517A2
(de)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
Rna-interferenz-vermittelte hemmung der genexpression von icam-1 (intercellular adhesion molecule 1) unter verwendung von sina (short interfering nucleic acid)
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20120004281A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
WO2010111464A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP3524275A1
(de)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
|
ES2661787T3
(es)
|
2009-05-01 |
2018-04-04 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con hemoglobina (hbf/hbg) por inhibición de transcrito antisentido natural para hbf/hbg
|
WO2010129799A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
|
WO2010129746A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
WO2010129861A2
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
DK2432881T3
(en)
|
2009-05-18 |
2018-02-26 |
Curna Inc |
TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
|
WO2010135695A2
(en)
|
2009-05-22 |
2010-11-25 |
Curna, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
US8791085B2
(en)
|
2009-05-28 |
2014-07-29 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
KR20230098713A
(ko)
|
2009-06-10 |
2023-07-04 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
KR101702689B1
(ko)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료
|
EP2443237B1
(de)
|
2009-06-16 |
2017-02-22 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem kollagengen durch hemmung des natürlichen antisense-transkripts zu einem kollagengens
|
DK3305302T3
(en)
|
2009-06-17 |
2018-11-19 |
Biogen Ma Inc |
COMPOSITIONS AND PROCEDURES FOR MODULATING SMN2 SPLITING BY AN INDIVIDUAL
|
WO2010151671A2
(en)
|
2009-06-24 |
2010-12-29 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
EP2446037B1
(de)
|
2009-06-26 |
2016-04-20 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
|
KR101885383B1
(ko)
|
2009-07-06 |
2018-08-03 |
웨이브 라이프 사이언시스 리미티드 |
신규한 핵산 프로드러그 및 그의 사용 방법
|
US9512164B2
(en)
|
2009-07-07 |
2016-12-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotide end caps
|
US8927513B2
(en)
|
2009-07-07 |
2015-01-06 |
Alnylam Pharmaceuticals, Inc. |
5′ phosphate mimics
|
US20120252869A1
(en)
|
2009-07-24 |
2012-10-04 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
WO2011017516A2
(en)
|
2009-08-05 |
2011-02-10 |
Curna, Inc. |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
CA2770104C
(en)
|
2009-08-11 |
2019-03-19 |
Opko Curna, Llc |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
EP2810643A3
(de)
|
2009-08-14 |
2015-03-11 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen aus Lipidformulierung und Verfahren zur Hemmung der Expression eines Gens aus dem Ebola-Virus
|
JP5943836B2
(ja)
|
2009-08-21 |
2016-07-05 |
カッパーアールエヌエー,インコーポレイテッド |
‘hsp70相互作用タンパク質c末端’(chip)に対する天然アンチセンス転写産物の阻害によるchip関連疾患の治療
|
CA2771172C
(en)
|
2009-08-25 |
2021-11-30 |
Opko Curna, Llc |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
NO2480669T3
(de)
|
2009-09-25 |
2018-04-07 |
|
|
MX2012004617A
(es)
|
2009-10-22 |
2012-05-08 |
Genentech Inc |
Metodos y composiciones para modular activacion de hepsina de proteina que estimula macrofago.
|
KR20120136345A
(ko)
|
2009-10-30 |
2012-12-18 |
노오쓰웨스턴 유니버시티 |
주형화된 나노컨쥬게이트
|
CN103003430A
(zh)
|
2009-11-12 |
2013-03-27 |
西澳大利亚大学 |
反义分子和治疗疾病的方法
|
MX338694B
(es)
|
2009-11-30 |
2016-04-27 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores.
|
EP3296398A1
(de)
|
2009-12-07 |
2018-03-21 |
Arbutus Biopharma Corporation |
Zusammensetzungen für nukleinsäurefreisetzung
|
ES2562499T3
(es)
|
2009-12-09 |
2016-03-04 |
Nitto Denko Corporation |
Modulación de la expresión de HSP47
|
JP6025567B2
(ja)
|
2009-12-16 |
2016-11-16 |
カッパーアールエヌエー,インコーポレイテッド |
膜結合転写因子ペプチダーゼ、部位1(mbtps1)に対する天然アンチセンス転写物の阻害によるmbtps1関連性疾患の治療
|
WO2011075656A1
(en)
|
2009-12-18 |
2011-06-23 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
JP6031356B2
(ja)
|
2009-12-23 |
2016-11-24 |
カッパーアールエヌエー,インコーポレイテッド |
Ucp2に対する天然アンチセンス転写産物の阻害による脱共役タンパク質2(ucp2)関連疾患の治療
|
EP2516648B1
(de)
|
2009-12-23 |
2017-11-08 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem häpatozyten-wachstumsfaktor (hgf) mittels hemmung des natürlichen antisense-transkripts gegen hgf
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
KR101853508B1
(ko)
|
2009-12-29 |
2018-06-20 |
큐알엔에이, 인크. |
종양 단백질 63 (p63)에 대한 천연 안티센스 전사체의 억제에 의한 p63에 관련된 질환의 치료
|
CN102791862B
(zh)
|
2009-12-31 |
2017-04-05 |
库尔纳公司 |
通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病
|
NO2521784T3
(de)
|
2010-01-04 |
2018-05-05 |
|
|
CN102822342B
(zh)
|
2010-01-06 |
2017-05-10 |
库尔纳公司 |
通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
US8946182B2
(en)
|
2010-01-25 |
2015-02-03 |
Curna, Inc. |
Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
CA2824843A1
(en)
|
2010-02-04 |
2011-08-11 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
EP2539452B1
(de)
|
2010-02-22 |
2016-07-27 |
CuRNA, Inc. |
Behandlung von durch pyrrolin-5-carboxylat-reduktase 1 (pycr1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für pycr1
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
PE20130214A1
(es)
|
2010-02-23 |
2013-03-11 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
ES2562817T3
(es)
|
2010-02-24 |
2016-03-08 |
Arrowhead Research Corporation |
Composiciones para el suministro dirigido de ARNip
|
JP6081798B2
(ja)
|
2010-02-26 |
2017-02-15 |
メモリアル スローン−ケタリング キャンサー センター |
miRNAに関連する癌を検出および処置するための方法および組成物およびmiRNAインヒビターおよび標的
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
EP2544703A4
(de)
|
2010-03-12 |
2013-09-18 |
Brigham & Womens Hospital |
Verfahren zur behandlung von gefässentzündungserkrankungen
|
WO2011123468A1
(en)
|
2010-03-29 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
US9102938B2
(en)
|
2010-04-01 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
2′ and 5′ modified monomers and oligonucleotides
|
KR101877065B1
(ko)
|
2010-04-02 |
2018-07-10 |
큐알엔에이, 인크. |
집락 자극 인자 3 (csf3)에 대한 자연 안티센스 전사체의 저해에 의한 집락 자극 인자 3 (csf3) 관련된 질환의 치료
|
RU2610661C2
(ru)
|
2010-04-09 |
2017-02-14 |
Курна, Инк. |
Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
|
NO2558478T3
(de)
|
2010-04-12 |
2018-08-04 |
|
|
US9145556B2
(en)
|
2010-04-13 |
2015-09-29 |
Life Technologies Corporation |
Compositions and methods for inhibition of nucleic acids function
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
US9156873B2
(en)
|
2010-04-28 |
2015-10-13 |
Isis Pharmaceuticals, Inc. |
Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
|
JP6005628B2
(ja)
|
2010-04-28 |
2016-10-12 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
|
EP3091027B1
(de)
|
2010-04-28 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
BR112012027547B1
(pt)
|
2010-04-29 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
Oligonucleotídeo modificado de fita simples, composição, e seus usos para tratar amiloidose transtirretina, reduzir os seus sintomas e para reduzir a expressão de mrna ou de proteína de transtirretina
|
EP2566893A1
(de)
|
2010-05-03 |
2013-03-13 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
|
JP2013525483A
(ja)
|
2010-05-03 |
2013-06-20 |
カッパーアールエヌエー,インコーポレイテッド |
サーチュイン(sirt)に対する天然アンチセンス転写物の阻害によるサーチュイン(sirt)関連疾患の治療
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
WO2011150007A2
(en)
|
2010-05-26 |
2011-12-01 |
Opko Curna Llc |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
KR101981705B1
(ko)
|
2010-05-28 |
2019-05-24 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
CA3102008A1
(en)
|
2010-06-02 |
2011-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
WO2011156713A1
(en)
|
2010-06-11 |
2011-12-15 |
Vanderbilt University |
Multiplexed interferometric detection system and method
|
WO2011163121A1
(en)
|
2010-06-21 |
2011-12-29 |
Alnylam Pharmaceuticals, Inc. |
Multifunctional copolymers for nucleic acid delivery
|
RU2588654C2
(ru)
|
2010-06-23 |
2016-07-10 |
Курна, Инк. |
Лечение заболеваний, связанных с альфа-субъединицей потенциалзависимого натриевого канала (scna), путем ингибирования природного антисмыслового транскрипта гена scna
|
JP5824515B2
(ja)
|
2010-06-24 |
2015-11-25 |
クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. |
Rhoaに対する二本鎖rna化合物およびその使用
|
EP2593547B1
(de)
|
2010-07-14 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem discs large homolog (dlg) durch hemmung des natürlichen antisense-transkripts an dlg
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012018754A2
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP3587574B1
(de)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
|
EP2609198B8
(de)
|
2010-08-24 |
2018-03-28 |
Sirna Therapeutics, Inc. |
Einsträngige rnai-mittel mit einem internen nukleinsäurefreien spacer
|
EP2609106A4
(de)
|
2010-08-26 |
2014-03-19 |
Merck Sharp & Dohme |
Durch rna-interferenz vermittelte inhibition der prolyl-hydroxylase-domäne-2 (phd2)-genexpression unter verwendung von short-interfering-nukleinsäuren (sina)
|
WO2012031243A2
(en)
|
2010-09-03 |
2012-03-08 |
Avi Biopharma, Inc. |
dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
|
JP5868324B2
(ja)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
WO2012044992A2
(en)
|
2010-09-30 |
2012-04-05 |
Agency For Science, Technology And Research (A*Star) |
Methods and reagents for detection and treatment of esophageal metaplasia
|
WO2012047968A2
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN103210086B
(zh)
|
2010-10-06 |
2017-06-09 |
库尔纳公司 |
通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
|
US20140031250A1
(en)
|
2010-10-07 |
2014-01-30 |
David Tsai Ting |
Biomarkers of Cancer
|
CN103180445B
(zh)
|
2010-10-22 |
2018-02-16 |
库尔纳公司 |
通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
|
CN103201387B
(zh)
|
2010-10-27 |
2018-02-02 |
库尔纳公司 |
通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病
|
EP2632472B1
(de)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Durch rna-interferenz vermittelte inhibition einer genexpression unter verwendung von short-interfering-nukleinsäuren (sina)
|
WO2012064824A1
(en)
|
2010-11-09 |
2012-05-18 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
AU2011325956B2
(en)
|
2010-11-12 |
2016-07-14 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
JP6071893B2
(ja)
|
2010-11-23 |
2017-02-01 |
カッパーアールエヌエー,インコーポレイテッド |
Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療
|
EP2649182A4
(de)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
US20130344053A1
(en)
|
2010-12-28 |
2013-12-26 |
University Of Rochester |
Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides
|
DK3202760T3
(da)
|
2011-01-11 |
2019-11-25 |
Alnylam Pharmaceuticals Inc |
Pegylerede lipider og deres anvendelse til lægemiddelfremføring
|
US9045749B2
(en)
|
2011-01-14 |
2015-06-02 |
The General Hospital Corporation |
Methods targeting miR-128 for regulating cholesterol/lipid metabolism
|
TWI593416B
(zh)
|
2011-02-02 |
2017-08-01 |
艾克厘德製藥公司 |
利用針對結締組織生長因子(ctgf)目標之反義化合物治療瘢痕或肥厚性疤痕之方法
|
US20140044644A1
(en)
|
2011-02-21 |
2014-02-13 |
University Of Zurich |
Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
|
US9562853B2
(en)
|
2011-02-22 |
2017-02-07 |
Vanderbilt University |
Nonaqueous backscattering interferometric methods
|
JP6000287B2
(ja)
|
2011-03-03 |
2016-09-28 |
クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. |
肺疾患および損傷を治療するための組成物および方法
|
JP6108628B2
(ja)
|
2011-03-29 |
2017-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Tmprss6遺伝子の発現を阻害する組成物および方法
|
KR102029657B1
(ko)
|
2011-06-08 |
2019-10-08 |
닛토덴코 가부시키가이샤 |
표적 약물 전달체 및 siRNA 활성을 증가시키는 화합물
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
US9011903B2
(en)
|
2011-06-08 |
2015-04-21 |
Nitto Denko Corporation |
Cationic lipids for therapeutic agent delivery formulations
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
CN103620036B
(zh)
|
2011-06-09 |
2016-12-21 |
库尔纳公司 |
通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
|
RU2711799C2
(ru)
|
2011-06-21 |
2020-01-22 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ иРНК ДЛЯ СХОДНОГО С АНГИОПОЭТИНОМ 3(ANGPTL3) БЕЛКА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
EP3388068A1
(de)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
|
CN103649103A
(zh)
|
2011-06-21 |
2014-03-19 |
阿尔尼拉姆医药品有限公司 |
用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
|
EP2723390B1
(de)
|
2011-06-23 |
2017-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
CN103796657B
(zh)
|
2011-07-19 |
2017-07-11 |
波涛生命科学有限公司 |
合成官能化核酸的方法
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
CN103874486A
(zh)
|
2011-09-06 |
2014-06-18 |
库尔纳公司 |
用小分子治疗与电压门控钠通道的α亚基(SCNxA)相关的疾病
|
WO2013040499A1
(en)
|
2011-09-14 |
2013-03-21 |
Northwestern University |
Nanoconjugates able to cross the blood-brain barrier
|
AU2012308320C1
(en)
|
2011-09-14 |
2018-08-23 |
Translate Bio Ma, Inc. |
Multimeric oligonucleotide compounds
|
JP6250543B2
(ja)
|
2011-09-27 |
2017-12-20 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
ジ脂肪族置換peg化脂質
|
MX2014004516A
(es)
|
2011-10-11 |
2015-01-16 |
Brigham & Womens Hospital |
Micro-arns en trastornos neurodegenerativos.
|
EA202090338A1
(ru)
|
2011-11-18 |
2021-04-30 |
Сарепта Терапьютикс, Инк. |
Функционально-модифицированные олигонуклеотиды и их субъединицы
|
EP2791160B1
(de)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modifizierte mrna zusammensetzungen
|
HUE041509T2
(hu)
|
2011-12-22 |
2019-05-28 |
Janssen Biopharma Inc |
Szubsztituált nukleozidok, nukleotidok és ezek analógjai
|
JP2016528161A
(ja)
|
2012-01-12 |
2016-09-15 |
クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. |
聴覚およびバランス障害を治療するための併用療法
|
TR201815503T4
(tr)
|
2012-03-15 |
2018-11-21 |
Curna Inc |
Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
US20150086584A1
(en)
|
2012-03-22 |
2015-03-26 |
University Of Miami |
Multi-specific binding agents
|
AU2013243949A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
AU2013243946A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of membrane proteins
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
CN104704122A
(zh)
|
2012-04-20 |
2015-06-10 |
艾珀特玛治疗公司 |
产热的miRNA调节剂
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
EP3919620A1
(de)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
|
US9273949B2
(en)
|
2012-05-11 |
2016-03-01 |
Vanderbilt University |
Backscattering interferometric methods
|
KR102028784B1
(ko)
|
2012-05-16 |
2019-10-04 |
트랜슬레이트 바이오 인코포레이티드 |
유전자 발현을 조절하기 위한 조성물 및 방법
|
EA201492123A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии семейства генов smn
|
SG11201500239VA
(en)
|
2012-07-13 |
2015-03-30 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
US20150216892A1
(en)
|
2012-08-03 |
2015-08-06 |
Aptamir Therapeutics, Inc. |
Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
|
DK2895608T3
(en)
|
2012-09-12 |
2019-01-21 |
Quark Pharmaceuticals Inc |
DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT
|
ES2872349T3
(es)
|
2012-09-12 |
2021-11-02 |
Quark Pharmaceuticals Inc |
Moléculas de oligonucleótidos bicatenarios para DDIT4 y métodos de uso de las mismas
|
US9694050B2
(en)
|
2012-10-21 |
2017-07-04 |
University Of Rochester |
THY1 (CD90) as a novel therapy to control adipose tissue accumulation
|
US10548962B2
(en)
|
2012-10-22 |
2020-02-04 |
The Board Of Regents For Oklahoma State University |
Use of the salmonella SPP type III secretion proteins as a protective vaccination
|
US9950053B2
(en)
|
2012-10-22 |
2018-04-24 |
The Board Of Regents For Oklahoma State University |
Use of the Salmonella SPP type III secretion proteins as a protective vaccination
|
LT2922554T
(lt)
|
2012-11-26 |
2022-06-27 |
Modernatx, Inc. |
Terminaliai modifikuota rnr
|
CA2892672A1
(en)
|
2012-12-06 |
2014-06-12 |
Merck Sharp & Dohme Corp. |
Disulfide masked prodrug compositions and methods
|
JP2016504050A
(ja)
|
2013-01-17 |
2016-02-12 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
EP2968391A1
(de)
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Langlebige polynukleotidmoleküle
|
MX366660B
(es)
|
2013-03-14 |
2019-07-18 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
|
EA202090946A3
(ru)
|
2013-03-14 |
2021-07-30 |
Сарепта Терапьютикс, Инк. |
Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
|
EP2971010B1
(de)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
NZ631289A
(en)
|
2013-03-15 |
2017-08-25 |
Sarepta Therapeutics Inc |
Improved compositions for treating muscular dystrophy
|
WO2014160871A2
(en)
|
2013-03-27 |
2014-10-02 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
WO2014172698A1
(en)
|
2013-04-19 |
2014-10-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
UY35582A
(es)
|
2013-05-22 |
2014-10-31 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
|
DK3007704T3
(da)
|
2013-06-13 |
2021-03-29 |
Antisense Therapeutics Ltd |
Kombinationsterapi til akromegali
|
PL3019619T3
(pl)
|
2013-07-11 |
2022-01-10 |
Modernatx, Inc. |
Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
|
AU2014292926B2
(en)
|
2013-07-25 |
2020-03-05 |
Exicure Operating Company |
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
RS59991B1
(sr)
|
2013-08-08 |
2020-04-30 |
Scripps Research Inst |
Metoda enzimskog in vitro obeležavanja specifičnog za položaj nukleinskih kiselina uvođenjem neprirodnih nukleotida
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CA2925107A1
(en)
|
2013-10-02 |
2015-04-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
CA2926218A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
KR102307389B1
(ko)
|
2013-10-04 |
2021-09-30 |
알닐람 파마슈티칼스 인코포레이티드 |
Alas1 유전자의 발현을 억제하기 위한 조성물 및 방법
|
KR102290214B1
(ko)
|
2013-11-21 |
2021-08-18 |
소마로직, 인크. |
시티딘-5-카르복스아미드 변형된 뉴클레오티드 조성물 및 그와 관련된 방법들
|
AU2014351482B2
(en)
|
2013-11-22 |
2020-08-20 |
Mina Therapeutics Limited |
C/EBP alpha short activating RNA compositions and methods of use
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
CA3107872A1
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
US9274117B2
(en)
|
2013-12-21 |
2016-03-01 |
Catholic University Industry Academic |
Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
|
KR102423317B1
(ko)
|
2014-01-16 |
2022-07-22 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
WO2015117010A2
(en)
|
2014-01-31 |
2015-08-06 |
Temple University Of The Commonwealth System Of Higher Education |
Bag3 as a target for therapy of heart failure
|
JP6736467B2
(ja)
|
2014-02-04 |
2020-08-05 |
ジェネンテック, インコーポレイテッド |
平滑化変異体及びその使用方法
|
EP3105331B1
(de)
|
2014-02-11 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
|
ES2891738T3
(es)
|
2014-04-09 |
2022-01-31 |
Scripps Research Inst |
Incorporación de nucleósidos trifosfato no naturales o modificados a células a través de transportadores de ácido nucleico trifosfato
|
MA39835A
(fr)
|
2014-04-17 |
2017-02-22 |
Biogen Ma Inc |
Compositions et procédés de modulation de l'épissage du smn2 chez un patient
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
PL3164113T3
(pl)
|
2014-06-04 |
2019-09-30 |
Exicure, Inc. |
Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych
|
EP4039807A1
(de)
|
2014-06-10 |
2022-08-10 |
Erasmus University Rotterdam Medical Center |
Zur behandlung der pompe-krankheit nützliche antisense-oligonukleotide
|
WO2015200697A1
(en)
|
2014-06-25 |
2015-12-30 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
CA2955250A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
BR112017001860A2
(pt)
|
2014-07-31 |
2018-02-27 |
Uab Research Foundation |
peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016033472A1
(en)
|
2014-08-29 |
2016-03-03 |
Children's Medical Center Corporation |
Methods and compositions for the treatment of cancer
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
US11390885B2
(en)
|
2014-09-15 |
2022-07-19 |
Children's Medical Center Corporation |
Methods and compositions to increase somatic cell nuclear transfer (SCNT) efficiency by removing histone H3-lysine trimethylation
|
WO2016049512A1
(en)
|
2014-09-26 |
2016-03-31 |
University Of Massachusetts |
Rna-modulating agents
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3212773B1
(de)
|
2014-10-29 |
2021-09-15 |
Massachusetts Eye and Ear Infirmary |
Effiziente abgabe von therapeutischen molekülen an zellen des innenohres
|
WO2016069912A1
(en)
|
2014-10-29 |
2016-05-06 |
Massachusetts Eye And Ear Infirmary |
Efficient delivery of therapeutic molecules in vitro and in vivo
|
EP3212794B1
(de)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
JP2017535552A
(ja)
|
2014-11-17 |
2017-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法
|
CA2968531A1
(en)
|
2014-11-21 |
2016-05-26 |
Northwestern University |
The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
US9517270B2
(en)
|
2014-12-08 |
2016-12-13 |
The Board Of Regents Of The University Of Texas System |
Lipocationic polymers and uses thereof
|
EP3230445B1
(de)
|
2014-12-12 |
2024-01-24 |
Tod M. Woolf |
Zusammensetzungen und verfahren zur editierung von nukleinsäuren in zellen mit oligonukleotiden
|
JP2018504380A
(ja)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Reversir(商標)化合物
|
EP3247988A4
(de)
|
2015-01-23 |
2018-12-19 |
Vanderbilt University |
Robustes interferometer und verfahren zur verwendung davon
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
|
WO2016135559A2
(en)
|
2015-02-23 |
2016-09-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
US10961532B2
(en)
|
2015-04-07 |
2021-03-30 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive X chromosome
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
EP3302489A4
(de)
|
2015-06-04 |
2019-02-06 |
Sarepta Therapeutics, Inc. |
Verfahren und verbindungen zur behandlung von krankheiten und leiden im zusammenhang mit lymphozyten
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
EP3310918B1
(de)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
WO2016210241A1
(en)
|
2015-06-26 |
2016-12-29 |
Beth Israel Deaconess Medical Center, Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
EP3314027A4
(de)
|
2015-06-29 |
2019-07-03 |
Caris Science, Inc. |
Therapeutische oligonukleotide
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
EP3324980B1
(de)
|
2015-07-17 |
2021-11-10 |
Alnylam Pharmaceuticals, Inc. |
Mehrfach gerichtete einheitlichen konjugate
|
US10941176B2
(en)
|
2015-07-28 |
2021-03-09 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
PE20181131A1
(es)
|
2015-09-02 |
2018-07-17 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
|
PT3349802T
(pt)
|
2015-09-14 |
2021-10-15 |
Univ Texas |
Dendrímeros lipocatiónicos e suas utilizações
|
JP2018532402A
(ja)
|
2015-09-24 |
2018-11-08 |
クリスパー セラピューティクス アーゲー |
Rnaプログラム可能エンドヌクレアーゼの新規のファミリーならびにゲノム編集および他の適用におけるそれらの使用
|
EP4089175A1
(de)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
|
WO2017072590A1
(en)
|
2015-10-28 |
2017-05-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of duchenne muscular dystrophy
|
CA3007424A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
MX2018005332A
(es)
|
2015-11-06 |
2018-11-09 |
Crispr Therapeutics Ag |
Materiales y metodos para tratamiento de la enfermedad de almacenamiento de glucogeno tipo 1a.
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
JP6932698B2
(ja)
|
2015-12-01 |
2021-09-08 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG |
アルファ1アンチトリプシン欠乏症の治療のための材料および方法
|
WO2017099579A1
(en)
|
2015-12-07 |
2017-06-15 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for pompe disease
|
WO2017106767A1
(en)
|
2015-12-18 |
2017-06-22 |
The Scripps Research Institute |
Production of unnatural nucleotides using a crispr/cas9 system
|
BR112018012894A2
(pt)
|
2015-12-23 |
2018-12-04 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de esclerose lateral amiotrófica e/ou degeneração lobular frontotemporal
|
EP3408649B1
(de)
|
2016-01-29 |
2023-06-14 |
Vanderbilt University |
Interferometrie mit antwortfunktion in freier lösung
|
EP3411078A1
(de)
|
2016-02-02 |
2018-12-12 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn-syndrom
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
EP3416689B1
(de)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn syndrome
|
JP7033072B2
(ja)
|
2016-02-25 |
2022-03-09 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
Smoc2を標的化する線維症のための治療方法
|
EP3429632B1
(de)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von erblicher haemochromatose
|
US10731166B2
(en)
|
2016-03-18 |
2020-08-04 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
JP6974349B2
(ja)
|
2016-04-18 |
2021-12-01 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
ヘモグロビン異常症の処置のための材料及び方法
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
EP3458032A4
(de)
|
2016-05-16 |
2019-12-25 |
The Board of Regents of The University of Texas System |
Kationische sulfonamid-aminolipide und amphiphile zwitterionische aminolipide
|
US11293017B2
(en)
|
2016-05-25 |
2022-04-05 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
EP3469083A1
(de)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
|
US20190218257A1
(en)
|
2016-06-24 |
2019-07-18 |
The Scripps Research Institute |
Novel nucleoside triphosphate transporter and uses thereof
|
CA3029119A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
US11174469B2
(en)
|
2016-06-29 |
2021-11-16 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
|
EP3481857A1
(de)
|
2016-07-06 |
2019-05-15 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von schmerbedingten erkrankungen
|
JP7305534B2
(ja)
|
2016-07-06 |
2023-07-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
疼痛関連障害を処置するための物質及び方法
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
EP3481430A4
(de)
|
2016-07-11 |
2020-04-01 |
Translate Bio Ma, Inc. |
Nukleinsäurekonjugate und verwendungen davon
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
EP3532638A4
(de)
|
2016-10-31 |
2020-07-29 |
University of Massachusetts |
Targeting von microrna-101-3p in der krebstherapie
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
US11753460B2
(en)
|
2016-12-13 |
2023-09-12 |
Seattle Children's Hospital |
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
KR20230166146A
(ko)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
US11197928B2
(en)
|
2017-01-13 |
2021-12-14 |
Board Of Regents, The University Of Texas System |
Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
|
CA3049980A1
(en)
|
2017-01-23 |
2018-07-26 |
Regeneron Pharmaceuticals, Inc. |
Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
|
EP3585899A1
(de)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von primärer hyperoxalurie typ 1 (ph1) und anderen mit dem alanin-glyoxylataminotransferase (agxt)-gen assoziierten erkrankungen oder störungen
|
US20200216857A1
(en)
|
2017-02-22 |
2020-07-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
EP3585898A1
(de)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von spinozerebellärer ataxie typ 1 (sca1) und anderen mit dem gen des proteins von spinozerebellärer ataxie typ 1 (atxn1) assoziierten erkrankungen oder störungen
|
EP3585807A1
(de)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung der parkinson-krankheit im frühstadium (park1) und anderer zustände oder störungen im zusammenhang mit dem synuclein-alpha (snca)-gen
|
US11920148B2
(en)
|
2017-02-22 |
2024-03-05 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
MA50278A
(fr)
|
2017-04-18 |
2020-02-26 |
Alnylam Pharmaceuticals Inc |
Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
|
EP3612232A1
(de)
|
2017-04-21 |
2020-02-26 |
The Broad Institute, Inc. |
Gezielte abgabe an beta-zellen
|
US11433131B2
(en)
|
2017-05-11 |
2022-09-06 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (SNAs)
|
CA3062506A1
(en)
|
2017-05-12 |
2019-05-23 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
AU2018300069A1
(en)
|
2017-07-11 |
2020-02-27 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
EP3652317A1
(de)
|
2017-07-13 |
2020-05-20 |
Alnylam Pharmaceuticals, Inc. |
Lactatdehydrogenase-a (ldha)-irna-zusammensetzungen und verfahren zu ihrer verwendung
|
MX2020001336A
(es)
|
2017-08-03 |
2020-08-20 |
Synthorx Inc |
Conjugados de citoquina para el tratamiento de enfermedades autoinmunes.
|
EP3679138B1
(de)
|
2017-09-08 |
2023-03-22 |
MiNA Therapeutics Limited |
Hnf4a-sarna-zusammensetzungen und verfahren zur verwendung
|
US20200208152A1
(en)
|
2017-09-08 |
2020-07-02 |
Mina Therapeutics Limited |
Stabilized sarna compositions and methods of use
|
KR20200067190A
(ko)
|
2017-10-17 |
2020-06-11 |
크리스퍼 테라퓨틱스 아게 |
A형 혈우병을 위한 유전자 편집용 조성물 및 방법
|
US20210180091A1
(en)
|
2017-10-26 |
2021-06-17 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
SG11202002940QA
(en)
|
2017-11-01 |
2020-04-29 |
Alnylam Pharmaceuticals Inc |
Complement component c3 irna compositions and methods of use thereof
|
EP3707256A1
(de)
|
2017-11-09 |
2020-09-16 |
CRISPR Therapeutics AG |
Selbstinaktivierende (sin) crispr/cas- oder crispr/cpf1-systeme und verwendungen davon
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
CN111727251A
(zh)
|
2017-11-21 |
2020-09-29 |
克里斯珀医疗股份公司 |
用于治疗常染色体显性色素性视网膜炎的材料和方法
|
CN111629747A
(zh)
|
2017-12-05 |
2020-09-04 |
沃泰克斯药物股份有限公司 |
Crispr-cas9修饰的cd34+人血色素干细胞和祖细胞及其用途
|
MA51138A
(fr)
|
2017-12-14 |
2020-10-21 |
Bayer Healthcare Llc |
Nouveaux systèmes d'endonucléases arn-programmables et leurs utilisations dans l'édition de génome et d'autres applications
|
US20200308588A1
(en)
|
2017-12-18 |
2020-10-01 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
CA3084632A1
(en)
|
2017-12-21 |
2019-06-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of usher syndrome type 2a
|
WO2019123430A1
(en)
|
2017-12-21 |
2019-06-27 |
Casebia Therapeutics Llp |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
EP3737762A1
(de)
|
2018-01-12 |
2020-11-18 |
CRISPR Therapeutics AG |
Zusammensetzungen und verfahren zur geneditierung von genen durch transferrin-targeting
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
US11268077B2
(en)
|
2018-02-05 |
2022-03-08 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
WO2019150196A1
(en)
|
2018-02-05 |
2019-08-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
WO2019161310A1
(en)
|
2018-02-16 |
2019-08-22 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
EP3758729A4
(de)
|
2018-02-26 |
2021-11-17 |
Synthorx, Inc. |
Il-15-konjugate und verwendungen davon
|
CN112424348A
(zh)
|
2018-03-19 |
2021-02-26 |
克里斯珀医疗股份公司 |
新颖的rna-可编程的内切核酸酶系统及其用途
|
WO2019186514A2
(en)
|
2018-03-30 |
2019-10-03 |
Rheinische Friedrich-Wilhelms-Universitat Bonn |
Aptamers for targeted activaton of t cell-mediated immunity
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
WO2019197845A1
(en)
|
2018-04-12 |
2019-10-17 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
EP3781689A1
(de)
|
2018-04-19 |
2021-02-24 |
Checkmate Pharmaceuticals, Inc. |
Synthetische rig-i-ähnliche rezeptoragonisten
|
WO2019210057A1
(en)
|
2018-04-27 |
2019-10-31 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Rapamycin resistant cells
|
JP7353301B2
(ja)
|
2018-05-07 |
2023-09-29 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
肝臓外送達
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
TW202023574A
(zh)
|
2018-08-13 |
2020-07-01 |
美商阿尼拉製藥公司 |
B型肝炎病毒(HBV)dsRNA劑組合物及其使用方法
|
US11987792B2
(en)
|
2018-08-16 |
2024-05-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
US20210292766A1
(en)
|
2018-08-29 |
2021-09-23 |
University Of Massachusetts |
Inhibition of Protein Kinases to Treat Friedreich Ataxia
|
CA3105385A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
JP7470107B2
(ja)
|
2018-09-28 |
2024-04-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
トランスサイレチン(TTR)iRNA組成物及びTTR関連眼疾患を治療又は予防するためのその使用方法
|
MX2021004455A
(es)
|
2018-10-17 |
2021-08-11 |
Crispr Therapeutics Ag |
Composiciones y métodos para administrar transgenes.
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
EP3898977A1
(de)
|
2018-12-20 |
2021-10-27 |
Praxis Precision Medicines, Inc. |
Zusammensetzungen und verfahren zur behandlung von kcnt1-assoziierten erkrankungen
|
SG11202106489RA
(en)
|
2018-12-20 |
2021-07-29 |
Vir Biotechnology Inc |
Combination hbv therapy
|
WO2020142693A1
(en)
|
2019-01-04 |
2020-07-09 |
Empirico Inc. |
Treatment of thymic stromal lymphopoietin (tslp) related diseases by inhibition of long-form tslp transcripts
|
JP2022517270A
(ja)
|
2019-01-16 |
2022-03-07 |
ジェンザイム・コーポレーション |
Serpinc1 iRNA組成物およびその使用方法
|
MA54952A
(fr)
|
2019-02-06 |
2022-05-11 |
Synthorx Inc |
Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
|
AU2020221340A1
(en)
|
2019-02-15 |
2021-09-16 |
Bayer Healthcare Llc |
Gene editing for hemophilia A with improved Factor VIII expression
|
WO2020171889A1
(en)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocking lipid accumulation or inflammation in thyroid eye disease
|
CA3132630A1
(en)
|
2019-03-12 |
2020-09-17 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
SG11202112240VA
(en)
|
2019-05-13 |
2021-12-30 |
Vir Biotechnology Inc |
Compositions and methods for treating hepatitis b virus (hbv) infection
|
CA3138915A1
(en)
|
2019-05-17 |
2020-11-26 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
US11879145B2
(en)
|
2019-06-14 |
2024-01-23 |
The Scripps Research Institute |
Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202120128A
(zh)
|
2019-08-15 |
2021-06-01 |
美商欣爍克斯公司 |
使用il-2接合物之免疫腫瘤學組合療法
|
US20220281911A1
(en)
|
2019-08-19 |
2022-09-08 |
Mina Therapeutics Limited |
Oligonucleotide conjugate compositions and methods of use
|
BR112022003046A8
(pt)
|
2019-08-23 |
2024-02-06 |
Synthorx Inc |
Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t
|
CN114616331A
(zh)
|
2019-09-03 |
2022-06-10 |
阿尔尼拉姆医药品有限公司 |
抑制lect2基因表达的组合物和方法
|
JP2022547078A
(ja)
|
2019-09-10 |
2022-11-10 |
シンソークス, インコーポレイテッド |
Il-2コンジュゲートおよび自己免疫疾患を治療するための使用方法
|
EP4038189A1
(de)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
|
EP4045652A1
(de)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
|
AU2020369515A1
(en)
|
2019-10-22 |
2022-04-21 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
CA3155202A1
(en)
|
2019-10-23 |
2021-04-29 |
Arthur M. Krieg |
Synthetic rig-i-like receptor agonists
|
TW202132567A
(zh)
|
2019-11-01 |
2021-09-01 |
美商阿尼拉製藥公司 |
亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
MX2022005251A
(es)
|
2019-11-04 |
2022-06-08 |
Synthorx Inc |
Conjugados de interleuquina 10 y sus usos.
|
EP4055165A1
(de)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon für die behandlung oder prävention ttr-assoziierter augenerkrankungen
|
JP2023500681A
(ja)
|
2019-11-06 |
2023-01-10 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
肝臓外送達
|
KR20220115946A
(ko)
|
2019-11-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
AU2020402885A1
(en)
|
2019-12-13 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (C9orf72) iRNA agent compositions and methods of use thereof
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
US20230054569A1
(en)
|
2019-12-18 |
2023-02-23 |
Alia Therapeutics Srl |
Compositions and methods for treating retinitis pigmentosa
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
WO2021163066A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
WO2021167841A1
(en)
|
2020-02-18 |
2021-08-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
JP2023516748A
(ja)
|
2020-03-06 |
2023-04-20 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
トランスサイレチン(ttr)の発現を阻害するための組成物および方法
|
CA3174725A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
EP4121534A1
(de)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
|
TW202204615A
(zh)
|
2020-03-26 |
2022-02-01 |
美商阿尼拉製藥公司 |
冠狀病毒iRNA組成物及其使用方法
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
KR20230008729A
(ko)
|
2020-04-06 |
2023-01-16 |
알닐람 파마슈티칼스 인코포레이티드 |
Myoc 발현을 사일런싱하기 위한 조성물 및 방법
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4133077A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
BR112022021813A2
(pt)
|
2020-04-27 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas
|
JP2023523790A
(ja)
|
2020-04-30 |
2023-06-07 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体因子B(CFB)iRNA組成物およびその使用方法
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
CA3162416C
(en)
|
2020-05-15 |
2023-07-04 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
EP4150090A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
EP4150086A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
EP4150077A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
CN115885042A
(zh)
|
2020-05-22 |
2023-03-31 |
波涛生命科学有限公司 |
双链寡核苷酸组合物及其相关方法
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
IL299063A
(en)
|
2020-06-18 |
2023-02-01 |
Alnylam Pharmaceuticals Inc |
Xanthine dehydrogenase (xdh) RNA compositions and methods of using them
|
US20230242621A1
(en)
|
2020-06-24 |
2023-08-03 |
Vir Biotechnology, Inc. |
Engineered hepatitis b virus neutralizing antibodies and uses thereof
|
TW202216203A
(zh)
|
2020-06-25 |
2022-05-01 |
美商欣爍克斯公司 |
Il-2接合物及抗egfr抗體之免疫腫瘤學組合治療
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
WO2022011214A1
(en)
|
2020-07-10 |
2022-01-13 |
Alnylam Pharmaceuticals, Inc. |
Circular sirnas
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
US20230392134A1
(en)
|
2020-09-30 |
2023-12-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法
|
KR20230084204A
(ko)
|
2020-10-09 |
2023-06-12 |
신톡스, 인크. |
Il-2 콘쥬게이트를 사용한 면역 종양학 치료법
|
BR112023006364A2
(pt)
|
2020-10-09 |
2023-05-09 |
Synthorx Inc |
Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
AU2021380809A1
(en)
|
2020-11-13 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
KR20230136130A
(ko)
|
2020-12-31 |
2023-09-26 |
알닐람 파마슈티칼스 인코포레이티드 |
시클릭-디설파이드 개질된 인산염 기반 올리고뉴클레오티드전구약물
|
WO2022147223A2
(en)
|
2020-12-31 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
EP4274896A1
(de)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
|
KR20230146048A
(ko)
|
2021-02-12 |
2023-10-18 |
알닐람 파마슈티칼스 인코포레이티드 |
슈퍼옥사이드 디스뮤타제 1(sod1) irna 조성물 및 슈퍼옥사이드 디스뮤타제 1- (sod1-) 관련 신경퇴행성 질환을 치료하거나 예방하기 위한 이의 사용 방법
|
TW202302148A
(zh)
|
2021-02-12 |
2023-01-16 |
美商欣爍克斯公司 |
使用il-2接合物和抗pd-1抗體或其抗原結合片段的肺癌組合療法
|
WO2022174101A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
EP4298220A1
(de)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2024515423A
(ja)
|
2021-02-26 |
2024-04-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
CA3212128A1
(en)
|
2021-03-04 |
2022-09-09 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
EP4305169A1
(de)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
|
US20240175033A1
(en)
|
2021-03-26 |
2024-05-30 |
Mina Therapeutics Limited |
TMEM173 saRNA Compositions and Methods of Use
|
KR20230162024A
(ko)
|
2021-03-29 |
2023-11-28 |
알닐람 파마슈티칼스 인코포레이티드 |
헌팅틴(HTT) iRNA 제제 조성물 및 이의 사용 방법
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
AU2022261124A1
(en)
|
2021-04-22 |
2023-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
IL307926A
(en)
|
2021-04-26 |
2023-12-01 |
Alnylam Pharmaceuticals Inc |
Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them
|
JP2024519293A
(ja)
|
2021-04-29 |
2024-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
シグナル伝達兼転写活性化因子6(STAT6)iRNA組成物およびその使用方法
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
EP4341405A1
(de)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
TW202317762A
(zh)
|
2021-06-02 |
2023-05-01 |
美商艾拉倫製藥股份有限公司 |
含有類PATATIN磷脂酶結構域3(PNPLA3)的iRNA組成物及其使用方法
|
WO2022256534A1
(en)
|
2021-06-03 |
2022-12-08 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
BR112023025224A2
(pt)
|
2021-06-04 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
US20240141312A1
(en)
|
2021-06-11 |
2024-05-02 |
Bayer Aktiengesellschaft |
Type v rna programmable endonuclease systems
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
KR20240026203A
(ko)
|
2021-06-30 |
2024-02-27 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
WO2023285431A1
(en)
|
2021-07-12 |
2023-01-19 |
Alia Therapeutics Srl |
Compositions and methods for allele specific treatment of retinitis pigmentosa
|
TW202333748A
(zh)
|
2021-07-19 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
|
WO2023003922A1
(en)
|
2021-07-21 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
EP4377458A1
(de)
|
2021-07-29 |
2024-06-05 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa-reduktase (hmgcr)-irna-zusammensetzungen und verfahren zur verwendung davon
|
CN117795074A
(zh)
|
2021-08-03 |
2024-03-29 |
阿尔尼拉姆医药品有限公司 |
转甲状腺素蛋白(TTR)iRNA组合物和其使用方法
|
WO2023014765A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
|
TW202334413A
(zh)
|
2021-08-13 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
第十二因子(F12)iRNA組成物及其使用方法
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
AU2022364838A1
(en)
|
2021-10-15 |
2024-04-11 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
WO2023069987A1
(en)
|
2021-10-20 |
2023-04-27 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss cross reference to related application
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202333749A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
補體因子b(cfb)irna組成物及其使用方法
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023118349A1
(en)
|
2021-12-21 |
2023-06-29 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
WO2023194359A1
(en)
|
2022-04-04 |
2023-10-12 |
Alia Therapeutics Srl |
Compositions and methods for treatment of usher syndrome type 2a
|
WO2023220744A2
(en)
|
2022-05-13 |
2023-11-16 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
EP4311579A1
(de)
|
2022-07-29 |
2024-01-31 |
Association Française contre les Myopathies |
B-zell-spezifische mabsirna-konjugate verbessern myasthenie
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024044352A1
(en)
|
2022-08-26 |
2024-02-29 |
The General Hospital Corporation |
Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024056880A2
(en)
|
2022-09-16 |
2024-03-21 |
Alia Therapeutics Srl |
Enqp type ii cas proteins and applications thereof
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|
WO2024105162A1
(en)
|
2022-11-16 |
2024-05-23 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|